Brokers

Brokers Offer Predictions for BioLineRx Ltd.’s Q2 2022 Earnings (NASDAQ:BLRX)


BioLineRx Ltd. (NASDAQ:BLRXGet Rating) – Research analysts at Zacks Investment Research issued their Q2 2022 earnings estimates for BioLineRx in a research report issued on Thursday, May 12th. Zacks Investment Research analyst J. Vandermosten expects that the biotechnology company will post earnings per share of ($0.15) for the quarter. Zacks Investment Research also issued estimates for BioLineRx’s Q3 2022 earnings at ($0.15) EPS, Q4 2022 earnings at ($0.15) EPS, FY2023 earnings at ($0.45) EPS and FY2024 earnings at ($0.15) EPS.

Separately, StockNews.com downgraded shares of BioLineRx from a “hold” rating to a “sell” rating in a research note on Sunday.

NASDAQ BLRX opened at $1.20 on Monday. BioLineRx has a 12 month low of $1.01 and a 12 month high of $3.62. The company has a 50-day moving average of $1.49 and a 200-day moving average of $1.92. The company has a market cap of $57.21 million, a P/E ratio of -2.14 and a beta of 2.04.

BioLineRx (NASDAQ:BLRXGet Rating) last posted its quarterly earnings data on Wednesday, March 16th. The biotechnology company reported ($0.08) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.06.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. LPL Financial LLC increased its position in BioLineRx by 11.4% during the 4th quarter. LPL Financial LLC now owns 73,576 shares of the biotechnology company’s stock worth $150,000 after purchasing an additional 7,500 shares in the last quarter. Advisor Group Holdings Inc. increased its position in BioLineRx by 105.9% during the 4th quarter. Advisor Group Holdings Inc. now owns 15,253 shares of the biotechnology company’s stock worth $31,000 after purchasing an additional 7,844 shares in the last quarter. Geneos Wealth Management Inc. increased its position in BioLineRx by 63.1% during the 4th quarter. Geneos Wealth Management Inc. now owns 28,950 shares of the biotechnology company’s stock worth $59,000 after purchasing an additional 11,200 shares in the last quarter. Schonfeld Strategic Advisors LLC acquired a new stake in BioLineRx during the 3rd quarter worth approximately $33,000. Finally, Morgan Stanley increased its position in BioLineRx by 5.9% during the 3rd quarter. Morgan Stanley now owns 240,128 shares of the biotechnology company’s stock worth $660,000 after purchasing an additional 13,306 shares in the last quarter. 5.23% of the stock is owned by hedge funds and other institutional investors.

BioLineRx Company Profile (Get Rating)

BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia.

See Also

Earnings History and Estimates for BioLineRx (NASDAQ:BLRX)



Receive News & Ratings for BioLineRx Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for BioLineRx and related companies with MarketBeat.com’s FREE daily email newsletter.

Source link

Related Articles

Leave a Reply

Your email address will not be published.

Back to top button
SUBSCRIBE TO OUR NEWSLETTER

Get our latest downloads and information first. Complete the form below to subscribe to our weekly newsletter.